Bipolar bozuklukta stabil yüksek doz risperidon sonrası oluşan hiponatremi: Bir olgu sunumu

Risperidon genellikle kullanılan bir atipik antipsikotiktir. Hiponatremi nadiren risperidonun bir yan etkisi olarak bildirilmiştir. Bipolar affektif bozukluğu olan, uygunsuz antidiüretik hormon salınımı sendromu gelişen, muhtemelen yüksek doz risperidonun neden olduğu bir hastayı sunuyoruz. Bipolar duygulanım bozukluğu olan ve günde 6 mg risperidon ve günde 1200 mg sodyum valproat kullanan 60 yaşındaki bir erkek hastada letarji, dengesiz yürüme, son 4 gün boyunca yönelim bozukluğu, ardından ateş ve sarı balgamla karakterize öksürük gelişti. Laboratuvar taraması sonucunda serum sodyum seviyesi 117 mmol/L, idrar sodyum konsantrasyonu 106 mmol/L idi ve plazma ozmolaritesi 260.57 mmol/Kg olarak hesaplandı. Uygunsuz antidiüretik hormon salınımı sendromu olarak değerlendirildi. Risperidonun çökeltici bir madde olduğu düşünülmüş ve tedavisi olanzapine değiştirilerek hiponatremisi düzeltilmiştir. Bu hastada yüksek doz risperidon tedavisi en muhtemel neden olup, oluşum mekanizması risperidonun 5-hidroksitriptamin 2A ve dopamin 2 reseptörlerine yüksek afinitesi ile ilişkili olabilir.

Hyponatremia induced by stable high dose risperidone in bipolar disorder: A case report

Risperidone is a commonly prescribed atypical antipsychotic. Hyponatremia has been reported rarely as an adverse effect of risperidone. We report a case of a patient with bipolar affective disorder, who developed the syndrome of inappropriate antidiuretic hormone secretion, probably induced by high dose risperidone. A 60-year-old male with bipolar affective disorder, who was on risperidone 6 mg per day and sodium valproate 1200 mg per day, developed lethargy, unsteady gait, disorientation for the past 4 days followed by fever and productive cough with yellow sputum. Laboratory screening revealed that the serum sodium level was 117 mol/L, the urine sodium concentration was 106 mmol/L and plasma osmolarity was 260.57 mmol/Kg. A diagnosis of the syndrome of inappropriate antidiuretic hormone secretion was made. Risperidone was thought of as a precipitating agent and changed over to olanzapine resulting in improvement in hyponatremia. In this patient, high-dose risperidone treatment was the most probable cause, and the mechanisms may be related to risperidone's high affinity for the 5-hydroxytryptamine 2A and dopamine 2 receptors.

___

  • 12. Bakhla AK, Guria RT, Kumar A. A suspected case of olanzapine induced hyponatremia. Indian J Pharmacol. 2014; 46:441-2.
  • 11. Rao N, Venkatasubramanian G, Korpade V, Behere R, Varambally S, Gangadhar B. Risperidone treatment for polydipsia and hyponatremia in schizophrenia: a case report. Turk Psikiyatri Derg. 2011;22:123-5.
  • 10. Knauer CS, Campbell JE, Galvan B, Bowman C, Osgood S, Buist S, et al. Validation of a rat in vivo [(3)H] M100907 binding assay to determine a translatable measure of 5-HT(2A) recep-tor occupancy. Eur J Pharmacol. 2008;591:136–41.
  • 9. de Leon J, Verghese C, Stanilla JK, Lawrence T, Simpson GM. Treatment of polydipsia and hyponatremia in psychiatric patients. Can clozapine be a new option? Neuropsychopharmacology. 1995;12:133–8.
  • 8. Albers HE, Karom M, Smith D. Serotonin and vasopressin interact in the hy-pothalamus to control communicative behavior. Neuroreport. 2002;13:931–3.
  • 7. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.
  • 6. Lareb, editor. Holland: Hertogenbosch; 2006. [Last accessed 2013 Aug 03]. The Netherlands Pharmacovigilance Centre. Olanzapine and hyponatraemia. Available from: http://www.lareb.nl/
  • 5. Epelde Gonzalo F. [Malignant neuroleptic syndrome and hyponatremia associated with risperidone poisoning]. An Med Interna. 2002;19:50. Spanish.
  • 4. Whitten JR, Ruehter VL. Risperidone and hyponatremia: a case report. Ann Clin Psychiatry. 1997;9:181-3.
  • 3. Meulendijks D, Mannesse CK, Jansen PA, van Marum RJ, Egberts TC. Antipsy-chotic-induced hyponatraemia: A systematic review of the published evidence. Drug Saf. 2010;33:101–14.
  • 2. Kim JH, Kim MJ. Association of adverse drug effects with subjective well-being in patients with schizophrenia receiving stable doses of risperidone. Clin Neuropharmacol. 2009;32:250–253.
  • 1. Heylen SL, Gelders YG. Risperidone, a new antipsychotic with serotonin 5-HT2 and dopamine D2 antagonistic properties. Clin Neuropharmacol. 1992;15:180A–181A.